8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Mar 19, 2026·SEC
Assembly Biosciences, Inc.(ASMB)Earnings, Financials & Key Ratios
ASMB•NASDAQ
Price updated Jun 19, 2026
AboutAssembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.Show more
- Revenue$72M+153.5%
- EBITDA-$12M+73.5%
- Net Income-$6M+84.8%
- EPS (Diluted)-0.55+91.8%
- Gross Margin99.82%-0.2%
- EBITDA Margin-16.58%+89.6%
- Operating Margin-16.76%+89.5%
- Net Margin-8.47%+94.0%
- ROE-5.1%+95.3%
ASMB Key Insights
Assembly Biosciences, Inc. (ASMB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y profit CAGR of 37.1%
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 1.3x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 86.7% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ASMB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ASMB Price & Volume
Assembly Biosciences, Inc. (ASMB) stock price & volume — 10-year historical chart
Loading chart...
ASMB Growth Metrics
Assembly Biosciences, Inc. (ASMB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-1.78%
3 Years-
TTM121.11%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM84.01%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM90.91%
Return on Capital
10 Years-45.35%
5 Years-53.29%
3 Years-44.34%
Last Year-8.65%
ASMB Recent Earnings
Assembly Biosciences, Inc. (ASMB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 6/12 qtrs (75%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.54+26.0%
$0.73
Rev
$8M-11.4%
$9M
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$2.48+586.3%
$0.51
Rev
$42M+472.2%
$7M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.72-44.0%
$0.50
Rev
$11M+44.6%
$7M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$1.33-103.6%
$0.65
Rev
$10M+3.2%
$9M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.54vs $0.73+26.0% | $8Mvs $9M-11.4% |
| Q2 2026 | Mar 19, 2026 | $2.48vs $0.51+586.3% | $42Mvs $7M+472.2% |
| Q4 2025 | Nov 10, 2025 | $0.72vs $0.50-44.0% | $11Mvs $7M+44.6% |
| Q3 2025 | Aug 6, 2025 | $1.33vs $0.65-103.6% | $10Mvs $9M+3.2% |
Based on last 12 quarters of dataView full earnings history →
ASMB Peer Comparison
Assembly Biosciences, Inc. (ASMB) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARWR | 11.52B | 81.82 | -6706.56 | 232.58% | -48.38% | -55.09% | 0.73 | |
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 REPL | 841.41M | 10.19 | -3.32 | -102.69% | 0.18 | |||
 GILD | 153.66B | 123.76 | 18.25 | 2.39% | 30.99% | 42.33% | 1.09 | |
 REGN | 63.37B | 609.94 | 14.70 | 0.99% | 29.65% | 14.32% | 0.09 | |
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 | |
 VRTX | 114.88B | 451.63 | 29.48 | 9.57% | 35.4% | 23.93% | 0.21 | |
 INCY | 19.62B | 98.22 | 15.32 | 21.22% | 26.71% | 29.31% | 0.01 |
Compare ASMB vs Peers
Assembly Biosciences, Inc. (ASMB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ASMB Income Statement
Assembly Biosciences, Inc. (ASMB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 9.02M | 14.8M | 15.96M | 79.11M | 6.25M | 0 | 7.16M | 28.52M | 72.3M | 71.1M |
Revenue Growth % | - | 64.15% | 7.83% | 395.55% | -92.09% | -100% | - | 298.16% | 153.52% | 121.11% |
Cost of Goods Sold | 44.23M | 72.74M | 85.32M | 101.34M | 0 | 69.08M | 48.9M | 0 | 129K | 16.18M |
COGS % of Revenue | 490.37% | 491.36% | 534.51% | 128.1% | - | - | 682.67% | - | 0.18% | - |
Gross Profit | -35.21M▲ 0% | -57.94M▼ 64.6% | -69.36M▼ 19.7% | -22.23M▲ 67.9% | 6.25M▲ 128.1% | -69.08M▼ 1204.6% | -41.74M▲ 39.6% | 28.52M▲ 168.3% | 72.17M▲ 153.1% | 54.91M▲ 0% |
Gross Margin % | -390.37% | -391.36% | -434.51% | -28.1% | 100% | - | -582.67% | 100% | 99.82% | 77.24% |
Gross Profit Growth % | -43770.17% | -64.56% | -19.72% | 67.95% | 128.13% | -1204.57% | 39.58% | 168.33% | 153.06% | - |
Operating Expenses | 61.25M | 107.54M | 33.35M | 42.54M | 138.94M | 25.03M | 22.91M | 73.94M | 84.42M | 68.52M |
OpEx % of Revenue | 679.09% | 726.42% | 208.93% | 53.78% | 2221.65% | - | 319.82% | 259.26% | 116.76% | - |
Selling, General & Admin | 17.02M | 34.8M | 34.86M | 36.86M | 28.78M | 23.93M | 22.91M | 18.01M | 19.61M | 19.78M |
SG&A % of Revenue | 188.72% | 235.06% | 218.37% | 46.6% | 460.19% | - | 319.82% | 63.14% | 27.12% | - |
Research & Development | 44.23M | 72.74M | 85.76M | 106.82M | 68.52M | 69.98M | 48.9M | 55.93M | 64.81M | 64.86M |
R&D % of Revenue | 490.37% | 491.36% | 537.22% | 135.04% | 1095.68% | - | 682.67% | 196.12% | 89.64% | - |
Other Operating Expenses | 0 | 0 | -87.26M | -101.14M | 41.64M | -68.88M | -48.9M | 0 | 0 | -1000K |
Operating Income | -52.23M▲ 0% | -92.73M▼ 77.6% | -102.71M▼ 10.8% | -64.78M▲ 36.9% | -132.69M▼ 104.8% | -94.11M▲ 29.1% | -64.65M▲ 31.3% | -45.42M▲ 29.7% | -12.12M▲ 73.3% | -13.55M▲ 0% |
Operating Margin % | -579.09% | -626.42% | -643.44% | -81.89% | -2121.65% | - | -902.5% | -159.26% | -16.76% | -19.05% |
Operating Income Growth % | -15.35% | -77.56% | -10.76% | 36.94% | -104.84% | 29.07% | 31.31% | 29.74% | 73.32% | - |
EBITDA | -52.01M | -92.09M | -102.22M | -64.08M | -132.22M | -93.62M | -64.2M | -45.29M | -11.99M | -13.43M |
EBITDA Margin % | -576.66% | -622.08% | -640.35% | -81.01% | -2114.2% | - | -896.22% | -158.8% | -16.58% | -18.88% |
EBITDA Growth % | -15.07% | -77.07% | -11% | 37.31% | -106.32% | 29.2% | 31.43% | 29.45% | 73.53% | 69.83% |
D&A (Non-Cash Add-back) | 219.22K | 643K | 494K | 691K | 466K | 498K | 450K | 129K | 129K | 122K |
EBIT | -52.23M | -92.73M | -104.22M | -59.09M | -91.05M | -93.01M | -64.65M | -45.42M | -12.12M | -11.86M |
Net Interest Income | 983K | 3.08M | 4.3M | 2.62M | 302K | 1.02M | 3.45M | 5.57M | 6M | 7.16M |
Interest Income | 983.21K | 3.08M | 4.3M | 2.62M | 302K | 1.02M | 3.45M | 5.57M | 6M | 7.16M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 368.2K | 3.08M | 5.85M | 2.62M | 302K | 1.02M | 3.45M | 5.57M | 6M | 7.16M |
Pretax Income | -51.86M▲ 0% | -89.65M▼ 72.9% | -96.86M▼ 8.0% | -62.15M▲ 35.8% | -132.39M▼ 113.0% | -93.09M▲ 29.7% | -61.2M▲ 34.3% | -39.85M▲ 34.9% | -6.12M▲ 84.6% | -6.38M▲ 0% |
Pretax Margin % | -575.01% | -605.59% | -606.78% | -78.57% | -2116.82% | - | -854.32% | -139.72% | -8.47% | -8.98% |
Income Tax | -9.05M | 1.1M | 774K | 0 | -2.53M | 0 | 33K | 330K | 0 | 0 |
Effective Tax Rate % | 17.45% | -1.23% | -0.8% | 0% | 1.91% | 0% | -0.05% | -0.83% | 0% | 0% |
Net Income | -42.81M▲ 0% | -90.75M▼ 112.0% | -97.63M▼ 7.6% | -62.15M▲ 36.3% | -129.85M▼ 108.9% | -93.09M▲ 28.3% | -61.23M▲ 34.2% | -40.18M▲ 34.4% | -6.12M▲ 84.8% | -6.38M▲ 0% |
Net Margin % | -474.66% | -613.02% | -611.63% | -78.57% | -2076.35% | - | -854.78% | -140.87% | -8.47% | -8.98% |
Net Income Growth % | 3.28% | -111.99% | -7.58% | 36.34% | -108.93% | 28.31% | 34.23% | 34.38% | 84.76% | 84.01% |
Net Income (Continuing) | -42.81M | -90.75M | -97.63M | -62.15M | -129.85M | -93.09M | -61.23M | -40.18M | -6.12M | -6.38M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -24.10▲ 0% | -39.80▼ 65.1% | -27.80▲ 30.2% | -15.00▲ 46.0% | -36.00▼ 140.0% | -22.82▲ 36.6% | -13.38▲ 41.4% | -6.69▲ 50.0% | -0.55▲ 91.8% | -0.38▲ 0% |
EPS Growth % | 6.23% | -65.15% | 30.15% | 46.04% | -140% | 36.61% | 41.37% | 50% | 91.78% | 90.91% |
EPS (Basic) | -24.10 | -39.80 | -27.80 | -15.00 | -36.00 | -22.82 | -13.38 | -6.69 | -0.55 | - |
Diluted Shares Outstanding | 1.78M | 2.28M | 3.51M | 3.97M | 3.61M | 4.03M | 4.58M | 6M | 11.21M | 16.9M |
Basic Shares Outstanding | 1.78M | 2.28M | 3.51M | 3.97M | 3.61M | 4.03M | 4.58M | 6M | 11.21M | 16.9M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ASMB Balance Sheet
Assembly Biosciences, Inc. (ASMB) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 123.12M | 222.5M | 282.78M | 224.49M | 154.2M | 96.97M | 133.79M | 115.5M | 254.55M | 232.61M |
Cash & Short-Term Investments | 119.95M | 218.08M | 274.04M | 216.41M | 146.63M | 91.61M | 130.25M | 112.08M | 248.11M | 226.6M |
Cash Only | 82.03M | 41.47M | 46.73M | 59.44M | 45.63M | 52.42M | 19.84M | 38.34M | 58.45M | 31.12M |
Short-Term Investments | 37.91M | 176.61M | 227.31M | 156.97M | 101M | 39.19M | 110.41M | 73.73M | 189.66M | 195.48M |
Accounts Receivable | 2.27M | 2.43M | 3.37M | 1.23M | 336K | 944K | 43K | 400K | 974K | 451K |
Days Sales Outstanding | 92.03 | 59.91 | 77.15 | 5.68 | 19.61 | - | 2.19 | 5.12 | 4.92 | 3 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | -3.2M | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 1.99M | 5.36M | 0 | 0 | 300K | 3.5M | 3.02M | 5.47M | 5.56M |
Total Non-Current Assets | 46.18M | 45.54M | 65.11M | 58.76M | 36.86M | 4.83M | 3.04M | 3.67M | 3.04M | 2.9M |
Property, Plant & Equipment | 860.03K | 557K | 13.8M | 10.73M | 7.18M | 3.94M | 2.72M | 3.35M | 2.73M | 2.58M |
Fixed Asset Turnover | 10.49x | 26.58x | 1.16x | 7.37x | 0.87x | - | 2.63x | 8.51x | 26.49x | 25.42x |
Goodwill | 12.64M | 12.64M | 12.64M | 12.64M | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 29M | 29M | 29M | 29M | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 3.35M | 0 | 0 | 0 | 27.97M | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 339.56K | 3.35M | 1.68M | 6.39M | 1.7M | 889K | 312K | 312K | 312K | 312K |
Total Assets | 169.3M▲ 0% | 268.05M▲ 58.3% | 347.89M▲ 29.8% | 283.25M▼ 18.6% | 191.06M▼ 32.5% | 101.79M▼ 46.7% | 136.82M▲ 34.4% | 119.17M▼ 12.9% | 257.59M▲ 116.2% | 235.51M▲ 0% |
Asset Turnover | 0.05x | 0.06x | 0.05x | 0.28x | 0.03x | - | 0.05x | 0.24x | 0.28x | 0.35x |
Asset Growth % | 72.55% | 58.32% | 29.79% | -18.58% | -32.55% | -46.72% | 34.41% | -12.9% | 116.16% | 363.42% |
Total Current Liabilities | 13.49M | 18.47M | 24.44M | 24.43M | 16.07M | 16.3M | 39.23M | 47.8M | 48.78M | 35M |
Accounts Payable | 2.12M | 3.69M | 1.73M | 4.6M | 2.66M | 2.49M | 461K | 585K | 1.17M | 1.13M |
Days Payables Outstanding | 17.53 | 18.53 | 7.4 | 16.56 | - | 13.17 | 3.44 | - | 3.31K | 26.65 |
Short-Term Debt | 0 | 0 | 3.19M | 0 | 0 | 0 | 0 | 0 | 569K | 590K |
Deferred Revenue (Current) | 5.23M | 5.1M | 6.41M | 0 | 0 | 0 | 30.91M | 37.62M | 36.9M | 65.98M |
Other Current Liabilities | 6.85M | 4.67M | 7.8M | 7.02M | 6.43M | 599K | 1.15M | 9.13M | 10.14M | 4.2M |
Current Ratio | 9.13x | 12.05x | 11.57x | 9.19x | 9.59x | 5.95x | 3.41x | 2.42x | 5.22x | 6.65x |
Quick Ratio | 9.13x | 12.05x | 11.57x | 9.19x | 9.59x | 5.95x | 3.49x | 2.42x | 5.22x | 6.65x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -23.65 |
Total Non-Current Liabilities | 42.69M | 38.92M | 50.23M | 18.24M | 6.06M | 2.83M | 56.5M | 38.01M | 2.06M | 1.9M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.9M |
Capital Lease Obligations | 0 | 0 | 9.08M | 6.72M | 3.33M | 101K | 1.12M | 2.63M | 2.06M | 6.62M |
Deferred Tax Liabilities | 2.14M | 3.25M | 10.51M | 2.53M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 108K | 0 | 0 | 0 | 2.73M | 0 | 35.38M | 0 | 0 |
Total Liabilities | 56.18M | 57.39M | 74.67M | 42.68M | 22.13M | 19.13M | 95.73M | 85.81M | 50.84M | 36.9M |
Total Debt | 0 | 0 | 12.27M | 10.13M | 6.48M | 3.46M | 2.34M | 3.09M | 2.63M | 2.49M |
Net Debt | -82.03M | -41.47M | -34.46M | -49.31M | -39.15M | -48.95M | -17.5M | -35.26M | -55.82M | -28.63M |
Debt / Equity | - | - | 0.04x | 0.04x | 0.04x | 0.04x | 0.06x | 0.09x | 0.01x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.19x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 2.13x |
Interest Coverage | - | - | - | - | - | - | - | - | - | - |
Total Equity | 113.12M▲ 0% | 210.65M▲ 86.2% | 273.22M▲ 29.7% | 240.58M▼ 11.9% | 168.93M▼ 29.8% | 82.66M▼ 51.1% | 41.1M▼ 50.3% | 33.36M▼ 18.8% | 206.75M▲ 519.8% | 198.61M▲ 0% |
Equity Growth % | 41.62% | 86.22% | 29.7% | -11.95% | -29.78% | -51.07% | -50.28% | -18.83% | 519.78% | 1706.54% |
Book Value per Share | 63.73 | 92.39 | 77.88 | 60.63 | 46.84 | 20.49 | 8.98 | 5.56 | 18.44 | 11.75 |
Total Shareholders' Equity | 113.12M | 210.65M | 273.22M | 240.58M | 168.93M | 82.66M | 41.1M | 33.36M | 206.75M | 198.61M |
Common Stock | 20.14K | 25K | 32K | 34K | 48K | 4K | 5K | 7K | 16K | 16K |
Retained Earnings | -251.04M | -341.79M | -439.42M | -501.57M | -631.43M | -724.52M | -785.75M | -825.92M | -832.05M | -841.13M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -392.39K | -347K | -201K | -270K | -419K | -803K | -81K | -211K | -41K | -368K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ASMB Cash Flow Statement
Assembly Biosciences, Inc. (ASMB) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 1.86M | -64.96M | -84.07M | -62.96M | -93.4M | -84.46M | 22.74M | -51.12M | -41.09M | -39.75M |
Operating CF Margin % | 20.62% | -438.79% | -526.64% | -79.59% | -1493.38% | - | 317.51% | -179.23% | -56.83% | - |
Operating CF Growth % | 105.33% | -3592.21% | -29.42% | 25.11% | -48.35% | 9.56% | 126.93% | -324.76% | 19.61% | 3606.5% |
Net Income | -42.81M | -90.75M | -97.63M | -62.15M | -129.85M | -93.09M | -61.23M | -40.18M | -6.12M | -6.38M |
Depreciation & Amortization | 219.22K | 643K | 494K | 691K | 466K | 498K | 450K | 129K | 129K | 96K |
Stock-Based Compensation | 8.6M | 28.48M | 20.56M | 21.85M | 5.24M | 6.59M | 5.12M | 3.12M | 4.68M | 3.96M |
Deferred Taxes | -9.05M | 1.1M | -774K | 0 | -2.53M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 615.13K | -229K | 2.82M | 6.96M | 44.69M | 3.66M | 2.06M | -2.24M | -1.5M | -652K |
Working Capital Changes | 44.28M | -4.21M | -9.53M | -30.31M | -11.4M | -2.12M | 76.34M | -11.95M | -38.28M | -36.78M |
Change in Receivables | -2.27M | -156K | -944K | 2.14M | 894K | -608K | 901K | 43K | -974K | -451K |
Change in Inventory | 1.1M | -601K | -3.01M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -244.19K | 1.57M | -1.96M | 2.87M | -1.94M | -166K | -2.03M | 124K | 586K | 254K |
Cash from Investing | -15.64M | -135.4M | -50.32M | 68.07M | 26.52M | 90.64M | -69.14M | 40.17M | -113.47M | -125.44M |
Capital Expenditures | -864.56K | -340K | -1.55M | -470K | -3.1M | -102K | -255K | -28K | -66K | -85K |
CapEx % of Revenue | 9.59% | 2.3% | 9.74% | 0.59% | 49.5% | - | 3.56% | 0.1% | 0.09% | 0.12% |
Acquisitions | -33.18B | -48.88M | -1.74M | 0 | 1.5M | 1.5M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 33.18B | 48.88M | 1.74M | -1.75M | 857K | 0 | 24K | 0 | 2.35M | 1.21M |
Cash from Financing | 67.24M | 159.79M | 139.65M | 7.6M | 53.06M | 614K | 13.82M | 29.45M | 174.67M | 172.89M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 67.24M | 155.43M | 134.66M | 5.45M | 52.81M | 325K | 13.69M | 29.29M | 174.67M | 172.89M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 4.37M | 4.99M | 2.15M | 258K | 289K | 129K | 155K | 0 | 0 |
Net Change in Cash | 53.46M▲ 0% | -40.56M▼ 175.9% | 5.26M▲ 113.0% | 12.71M▲ 141.6% | -13.82M▼ 208.7% | 6.79M▲ 149.1% | -32.58M▼ 579.7% | 18.5M▲ 156.8% | 20.11M▲ 8.7% | 7.71M▲ 0% |
Free Cash Flow | 995.52K▲ 0% | -65.3M▼ 6659.2% | -85.62M▼ 31.1% | -65.18M▲ 23.9% | -96.49M▼ 48.0% | -84.56M▲ 12.4% | 22.49M▲ 126.6% | -51.15M▼ 327.4% | -41.16M▲ 19.5% | -39.84M▲ 0% |
FCF Margin % | 11.04% | -441.08% | -536.37% | -82.39% | -1542.88% | - | 313.95% | -179.33% | -56.93% | -56.03% |
FCF Growth % | 102.84% | -6659.2% | -31.12% | 23.88% | -48.05% | 12.36% | 126.59% | -327.43% | 19.52% | 29.13% |
FCF per Share | 0.56 | -28.64 | -24.41 | -16.43 | -26.75 | -20.96 | 4.91 | -8.52 | -3.67 | -2.36 |
FCF Conversion (FCF/Net Income) | -0.04x | 0.72x | 0.86x | 1.01x | 0.72x | 0.91x | -0.37x | 1.27x | 6.71x | 6.24x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 421K | 0 | 0 |
ASMB Key Ratios
Assembly Biosciences, Inc. (ASMB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -44.36% | -56.06% | -40.36% | -24.19% | -63.42% | -74% | -98.95% | -107.92% | -5.1% | -4.21% |
Return on Invested Capital (ROIC) | -95.09% | -69.46% | -37.77% | -22.6% | -62% | -86.35% | -169.2% | -313.93% | -12.2% | -8.45% |
Gross Margin | -390.37% | -391.36% | -434.51% | -28.1% | 100% | - | -582.67% | 100% | 99.82% | 77.24% |
Net Margin | -474.66% | -613.02% | -611.63% | -78.57% | -2076.35% | - | -854.78% | -140.87% | -8.47% | -8.98% |
Debt / Equity | - | - | 0.04x | 0.04x | 0.04x | 0.04x | 0.06x | 0.09x | 0.01x | 0.01x |
FCF Conversion | -0.04x | 0.72x | 0.86x | 1.01x | 0.72x | 0.91x | -0.37x | 1.27x | 6.71x | 6.24x |
Revenue Growth | - | 64.15% | 7.83% | 395.55% | -92.09% | -100% | - | 298.16% | 153.52% | 121.11% |
Related:ASMB Dividend History·ASMB Revenue History·ASMB Price History·ASMB P/E History·ASMB Financial Ratios·ASMB Institutional Holders
ASMB SEC Filings & Documents
Assembly Biosciences, Inc. (ASMB) SEC filings — annual & quarterly reports (10-K, 10-Q)
ASMB Frequently Asked Questions
Assembly Biosciences, Inc. (ASMB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Assembly Biosciences, Inc. (ASMB) reported $71.1M in revenue for fiscal year 2025.
Assembly Biosciences, Inc. (ASMB) grew revenue by 153.5% over the past year. This is strong growth.
Assembly Biosciences, Inc. (ASMB) reported a net loss of $6.4M for fiscal year 2025.
Dividend & Returns
Assembly Biosciences, Inc. (ASMB) has a return on equity (ROE) of -5.1%. Negative ROE indicates the company is unprofitable.
Assembly Biosciences, Inc. (ASMB) had negative free cash flow of $39.8M in fiscal year 2025, likely due to heavy capital investments.